Skip Navigation.

Viagra Turns 5

December 31st, 2007

Title: Viagra Turns 5 ,  By: Gorman, Christine, Time South Pacific, 08180628, 1/20/2003, Issue 2

Section: YOUR TIME


Early safety concerns proved baseless, and now the competition is heating up

If this story were an E-mail message, chances are you would have trashed it by now. That’s because the subject is Viagra, the little blue pill that allows many otherwise impotent men to achieve erection and, not coincidentally, continues to generate a torrent of Internet spam. Hard to believe it has been almost five years since Viagra was approved by the Food and Drug Administration. In that time early fears that the drug might cause nerve damage to the eye or directly trigger cardiac deaths have been laid to rest, while its status as a cultural phenomenon has grown. (The pill has an entry in the Shorter Oxford English Dictionary.)

Viagra may soon get some tough competition. GlaxoSmithKline and Bayer are on schedule to bring a drug called vardenafil (trade name: Levitra) to market in Europe later this year. Another drug, called tadalafil (Cialis), is also being launched there. Like Viagra, these new pills facilitate an erection by trapping more blood in the penis. Pfizer, the maker of Viagra, believes both new drugs infringe on its patent. The company lost its case in Europe; another lawsuit in the U.S. is pending.

Meanwhile, the uses for Viagra seem to be growing. A study in the Journal of the American Medical Association two weeks ago showed that Viagra successfully counteracts some of the sexual side effects experienced by men who take Prozac or similar antidepressants. Researchers at Pfizer are also intrigued by reports that because it dilates blood vessels, Viagra may help reduce pulmonary hypertension, an often deadly and difficult-to-treat form of high blood pressure that affects the lungs.

Viagra users are only getting younger. Five years ago, the typical patient was a married man in his 60s. Nowadays, he’s still married but more likely to be in his 50s. One trend that has started to worry public-health officials, however, is the growing recreational use of Viagra in some settings. Gay men seem to be at the vanguard of this trend. Viagra, often in combination with illegal drugs like ecstasy, enables patrons of sex clubs to have sex with more partners, which increases their risk of contracting sexually transmitted diseases (STDs) like syphilis and aids. “One out of three sexually active gay men at our STD clinics has used Viagra in the past year,” says Dr. Jeffrey Klausner, director of STD Prevention and Control Services in San Francisco. The same was true for 1 of 14 heterosexual men at the clinics.

Despite the potential for abuse and the usual risks associated with any physical activity like sex, Viagra has been a boon to many men. “It is still the most patient-friendly method of treating erectile dysfunction,” says Dr. Ira Sharlip, assistant clinical professor of urology at the University of California at San Francisco. Although Viagra doesn’t work for everyone, it’s what most patients want to try first, before turning to such alternatives as injections, vacuum pumps and surgical implants. Perhaps all those unsolicited e-mail come-ons are a small price to pay after all.

For more on sexual dysfunction, visit www.smsna.org

PHOTO (COLOR): LITTLE BLUE PILLS From sex aid to Internet spam

~~~~~~~~

By Christine Gorman


Copyright of Time South Pacific is the property of Time Inc. and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Time South Pacific, 1/20/2003 Issue 2, p95, 1p

VIAGRA: WHAT EVERY PHYSICIAN SHOULD KNOW

December 31st, 2007

Title: VIAGRA: WHAT EVERY PHYSICIAN SHOULD KNOW ,  By: Kloner, Robert A., ENT: Ear, Nose & Throat Journal, 01455613, Sep98, Vol. 77, Issue 9

Section: ENT SPECIAL FEATURE




Abstract

Viagra, an oral drug taken one hour prior to sexual activity, improves erectile function in the majority of men with erectile dysfunction who receive it. It is not an aphrodisiac and therefore will not work without sexual stimulation. The drug is absolutely contraindicated in patients on organic nitrates, as this combination can lead to severe drops in blood pressure. Patients with heart disease, suspected heart disease and risk factors for heart disease should discuss with their physicians the safety of resuming sexual activity. A cardiac work-up, including exercise treadmill testing, should be considered in appropriate patients.


Introduction

On March 27,1998, the FDA approved sildenafil (Viagra) as the first oral agent for the treatment of male erectile dysfunction. This new drug has received wide coverage in the media and on talk shows and has spurred an entire generation of new jokes; most importantly, however, it has awakened the public consciousness to the problem of erectile dysfunction (ED). This issue is now being discussed openly by patients, spouses and healthcare providers. The purpose of this article is to describe ED, and to discuss the various treatment options and the efficacy and warnings regarding this remarkable new drug.


What is ED?

A National Institutes of Health Consensus Conference defined ED as the inability of a man to achieve an erect penis as part of the overall multifaceted process of male sexual function.(n1) This process involves not only achieving an erection but maintaining it for satisfactory sexual intercourse. Prior to this report the term “impotence” usually was used, as can be seen throughout the literature. The NIH Consensus group suggested that this term be dropped because it had pejorative implications. Thus, in this article we will use the term ED.


How common is ED?

According to various estimates, 10 to 30 million men in the United States are affected. One study that examined the prevalence of ED was the Massachusetts Male Aging Study.2 It showed that among 1,290 men ages 40 to 70 years, 52% complained of some degree of ED. There are various grades of ED: “Complete” ED refers to the inability to ever achieve a satisfactory erection for sexual activity; “mild” implies only an occasional or rare difficulty; “moderate” is somewhere in between. In this study, complete ED was reported by 10% of the men enrolled; moderate ED by 25%; and mild ED by 17%. Complete ED was present in 5% of men 40 years of age and in 15% of men 70 years of age. With the advent of Viagra, it is likely that many more men with ED will now come forward for treatment, causing an apparent increase in the prevalence rates of ED.


What causes ED?

There are numerous causes, and they can be broken down into several broad categories. Psychogenic, vascular and neurogenic are the major categories, followed by endocrine abnormalities, structural abnormalities, renal failure/ dialysis and the use of certain drugs? In the past, most cases of ED were labeled psychogenic, but we now know that this is usually not so. The vast majority of men over the age of 50 years experience ED as a result of vascular disease. It is especially prevalent in older men with diabetes because of a vascular as well as a neurogenic component.

Risk factors for atherosclerotic vascular disease are known contributors to ED.(n2,n6-n9) These include smoking, diabetes, low levels of high-density lipoprotein (HDL) cholesterol, high levels of total and low-density lipoprotein (LDL) cholesterol, and hypertension. Neurogenic causes of ED include neuropathies (such as diabetic or alcoholic neuropathy), multiple sclerosis, spinal cord injuries, nerve disruption associated with prostate surgery, and strokes.

Medications that have been associated with ED include antihypertensive drugs–especially the thiazide diuretics-and a host of others, such as Beta-blockers, reserpine, methyldopa and hydralazine. Alcohol, antidepressants, cancer chemotherapeutic agents and certain hormones also are associated with this condition. Endocrine abnormalities that can cause ED include hypogonadism (low testosterone levels), hyperprolactinemia (usually secondary to a pituitary tumor) and hypo- or hyperthyroidism.

Structural abnormalities leading to ED include Peyronie’s disease (fibrosis of the corpus cavernosum); priapism (painful, persistent erection associated with diseases such as sickle cell anemia, multiple myeloma and leukemia, which can ultimately damage the erectile tissue); and trauma.


Viagra: A Noninvasive Treatment Option

Viagra is the first FDA-approved oral agent specifically indicated for the treatment of ED.(n10) Prior to its availability, few desirable options for the treatment of ED existed. Until that time, treatment was limited to intracavernosal injections of vasodilators, such as alprostadil (prostaglandin E); intraurethral suppositories of alprostadil; vacuum tumescence devices; penile prostheses; counseling for psychogenic ED; alternative oral therapies (such as yohimbine); and vascular surgery. Additional oral forms of therapy for ED (e.g., oral phentolamine, apomorphine) are being studied, but as yet none has been approved by the FDA.

Efficacy

There is no question that Viagra works.(n11,n12) Pfizer Pharmaceuticals reports that in a large series of men (n = 3,000),(n13) only 24% reported improved erections after receiving placebo, while 63% had improved erections after receiving 25 mg of Viagra; 75% had improvement at 50 mg; and 82% had improvement at the 100 mg dose. The drug was effective across ages, races and etiologies of ED. Its effectiveness was diminished in patients with diabetes and radical prostatectomies when compared with other groups of men with ED. The drug improved the frequency at which attempted sexual intercourse was successful and enhanced orgasmic function, intercourse satisfaction and overall satisfaction.(n12)

It is important to note that the drug does not increase sexual desire. Viagra is not an aphrodisiac. In order for it to work there must be sexual stimulation (visual, tactile, auditory, etc.).

Mechanisms of Action

Basically, Viagra works as a vasodilator.(n10) With sexual stimulation, nitric oxide (NO) is released by nerve cells and endothelial cells within the corpus cavemosum (the spongy tissue within the penis that is responsible for erection). NO stimulates the formation of cyclic guanosine monophosphate (GMP), which causes dilation of the arteries, arterioles and sinusoids of the corpus cavernosum, causing it to fill with blood and stiffen. Cyclic GMP is then degraded by phosphodiesterase-5 (PDE-5), an enzyme that is highly concentrated in genital tissue. In men with ED, the problem is often that the cyclic GMP is not present in high enough concentrations to either develop or maintain an erection. Viagra’s mechanism of action is to inhibit PDE-5, resulting in higher concentrations of cyclic GMP, better vasodilation and, hence, erection.

Pharmacologic Characteristics

Viagra is absorbed rapidly, reaching peak drug levels in 30 to 120 minutes.13 A high-fat meal can slow its rate of absorption, so patients should be warned not to eat fatty meals prior to its use. Viagra is primarily cleared by hepatic enzymes. Inhibitors of liver isoenzymes involved in the drug’s breakdown can increase Viagra levels. Therefore, the dose of Viagra might need to be lowered when patients are on certain agents, such as cimetidine, erythromycin and certain antifungal agents,(n13) or in patients with liver disease.

Viagra, when taken alone, can cause small (usually clinically imperceptible) drops in systemic blood pressure; when given with common antihypertensive drugs (diuretics, angiotensin-converting enzyme [ACE] inhibitors, calcium blockers, IS-blockers, or a-blockers), it resulted in the same small drops that would have been expected even if the patient had not been taking the antihypertensive drug. Thus, while it had a small additive effect on lowering blood pressure, it did not have a synergistic effect. It is likely that future studies will continue to examine the effect of Viagra on blood pressure. Other studies will be looking at potential interactions between Viagra and protease inhibitors. In patients with severe liver disease or renal disease the lowest dose should be used initially.(n13)

Dosage Recommendations

The current recommended dose is one 50 mg tablet one hour before sexual activity, but it can be administered from four hours to 30 minutes before sex. The drug is taken on an as-needed basis, only prior to sexual activity, and it therefore needn’t be taken chronically. If the 50 mg dose is ineffective and the patient does not experience severe side effects, the dose can be increased to 100 my. In patients who develop severe side effects at 50 my, reducing the dose to 25 mg may be considered, although efficacy is generally lower at this dose. The drug should not be taken more than once a day.(n13)

Contraindications and Side Effects

There is one major contraindication to taking Viagra: It absolutely must not be given to any patient taking organic nitrates.(n13) These include agents such as sublingual nitroglycerin tablets and sprays; long-acting nitrates such as isosorbide dinitrate and isosorbide mononitrate; nitroglycerin patches or pastes; and other forms. In most cases, patients will be receiving nitrates for angina pectoris.

Not all men taking organic nitrates are doing so for medical reasons. Prevalent in the gay community is the recreational use of the drugs amyl nitrite and amyl nitrate (so-called “poppers”–alleged sexual enhancers). These are also organic nitrates and must not be taken concomitantly with Viagra. When the drug is administered in the presence of either of these organic nitrates (which are NO donors), there is a marked synergistic vasodilator effect, resulting in large drops in systemic blood pressure.

Side effects of Viagra are primarily related to its effects as a vasodilator and include headache (16%), flushing (10%), dyspepsia (7%), nasal congestion (4%) and diarrhea (3%).(n13) In addition, approximately 3% of men taking the drug may experience a transient visual disturbance reported as a blue-green color tinge, increased sensitivity to light, or blurred vision. It is important to note that priapismis not a side effect of Viagra. The drug is not approved for use in women, and its effect on human pregnancy is not yet known.

Safety

As of three months after Viagra’s release, 30 deaths had occurred among approximately 2 million men using it.(n14) Some of these deaths were associated with concomitant use of nitrates.(n15) Others occurred primarily in older men with histories of heart disease, hypertension, diabetes or other chronic diseases. It is conceivable that some of these men might have had cardiovascular events associated with sexual activity, and that these would have occurred regardless of whether they had used Viagra. It has been documented that there is a small, although finite, increase in the risk of myocardial infarction associated with sexual activity,(n16) arising from increased heart rate and elevated blood pressure, and hence, an increase in the cardiac workload.(n17)

For patients who have known coronary artery disease, heart disease or risk factors for coronary artery disease and want to try Viagra, consider performing a cardiac evaluation, including an exercise treadmill test, to help gauge the safety of a return to sexual activity. Ability to pass an exercise stress test without developing signs of ischemia would be reassuring to both the patient and spouse.

A preliminary statement of the American College of Cardiology/American Heart Association suggested that clinicians should exercise caution in using Viagra in patients with active coronary ischemia, patients with congestive heart failure and borderline low blood pressure and low volume status, patients on complicated drug regimens for the treatment of hypertension, and patients on drugs or with conditions that might prolong Viagra’s half-life.(n18)


Discussion

Although Viagra has only been available for approximately three months (at the time of this writing), it has already begun to change the sexual landscape in the United States, much as the birth control pill did in the 1960s. For the first time there is an orally administered drug that can be taken one hour before sexual activity, that can improve ED in most men and that has the potential to improve male-female relationships. Already, however, the drug is the subject of controversy. Obviously, there are concerns about the number of deaths that have occurred, but epidemiologic studies have suggested that mortality associated with cardiovascular disease among men in the United States occurs with a frequency of 185 to 275 per million per month.(n19) Therefore, an incidence of 30 deaths per 2 million men taking Viagra in three months seems quite low.

The FDA has reviewed the data regarding these deaths and did not consequently change Viagra’s labeling.(n15) Nevertheless, it is likely that these cases will continue to be reviewed, as will the potential for drug-drug interactions, which are as yet unknown. In the meantime, the nitroglycerin-Viagra contraindication stands, so physicians should discuss this issue with their patients; and in those with a possible cardiac risk associated with sexual activity, they should consider a cardiac work-up.

An additional area of controversy involves various HMOs’ unwillingness to pay for treatment with Viagra. Some HMOs have agreed to pay and others have not, primarily because of its cost and the view that Viagra is more of a “lifestyle” drug than one necessary for the treatment of a disease.

Editor’s note: Since its approval by the FDA for the treatment of male erectile dysfunction, sildenafil (Viagra) has been the focus of a virtual media blitz. In the six short months that the drug has been available, patients in unprecedented numbers have gone to their physicians (any physicians) requesting the drug. Because ENT practitioners are not immune to such requests, it is incumbent upon us to familiarize ourselves with any and all information pertaining to this drug, including its desired effects and possible adverse effects. Dr. Kloner began consulting and lecturing on Viagra before its introduction for general use. He wrote this article at the request of the editor.

The Heart Institute, Good Samaritan Hospital, and Section Cardiology, University of Southern California, Los Angeles, California.

Reprint requests to: Robert A. Kloner, MD, PhD, Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017.


References

(n1.)
NIH Consensus Development Panel on Impotence. NIH Consensus Conference: Impotence. JAMA 1993;270:83-90.

(n2.)
Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.

(n3.)
Benson GS. Boileau MA. The penis: Sexual function and dysfunction. In: Adult and Pediatric Urology, Third Edition. Gillenwater JY, Grayhack JT, Howards SS, et al, editors. St. Louis: Mosby, 1996:1951-93.

(n4.)
Lue TF, Broderick G. Evaluation and nonsurgical management of erectile dysfunction and priapism. In: Campbell’s urology, 7th Edition. Walsh PC, editor. Philadelphia: Saunders, 1998:1181-1207.

(n5.)
McConnell JD, Wilson JD. Impotence. In: Harrison’s Principles of Internal Medicine, 14th Edition. Fauci AS, et al, editors. New York: McGraw-Hill, 1998:286-9.

(n6.)
Virag R, Bouilly P. Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985 ;8422:181-4.

(n7.)
Wei M, Macera CA, Davis DR, et al. Total cholesterol and highdensity lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994; 140:930-7.

(n8.)
Klein R, Klein BEK, Lee KE, et al. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 1996;19:135-41.

(n9.)
Greenstein A, Chen J, Miller H, et al. Does severity of ischemic coronary disease correlate with erectile function? International Journal of Impotence Research 1997;9:123-6.

(n10.)
Licht MR. Sildenafil (Viagra) for treating male erectile dysfunction. Cleveland Clin J Med 1998;65:301-4

(n11.)
Boolell NI, Gepi-Attee S, Gingell JC, et al. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Brit J Urol 1996;78:257-61.

(n12.)
Goldstein I, Lue TF, Padma-Nathan H, et al, for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-1404.

(n13.)
Viagra (sildenafil nitrate). Full prescribing information. Monograph. Pfizer U.S. Pharmaceuticals, April 1998.

(n14.)
Sharpe R. FDA received adverse data about Viagra. The Wall Street Journal 1998 June 29; B6.

(n15.)
Cimons M. FDA details death of 16 Viagra users. Los Angeles Times 1998 June 10; A24.

(n16.)
Muller JE, Mittleman MA, Maclure M, et al, for the Determinants of Myocardial Infarction Onset Study Investigators. Triggering myocardial infarction by sexual activity: Low absolute risk and prevention by regular physical exertion. JAMA 1996;275:1405-9.

(n17.)
E1-Sakka AI, Lue TF. Does a heart attack mean the end of sexual life? ACC Educational Highlights, Winter 1996;6-9.

(n18.)
Hurter AM, Cheitlin MD, et al. Summary statement of the American College of Cardiology and the American Heart Association on the use of sildenafil (Viagra) in patients at clinical risk from cardiovascular effects. Aug. 10, 1998.

(n19.)
American Heart Association. 1998 Heart and Stroke-Statistical Update. Dallas, Texas: American Heart Association Monograph, 1997.

~~~~~~~~

By Robert A. Kloner, MD, PhD, Los Angeles , California

Adapted by MD, PhD


Copyright of ENT: Ear, Nose & Throat Journal is the property of Medquest Communications and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: ENT: Ear, Nose & Throat Journal, Sep98, Vol. 77 Issue 9, p783, 4p

ED’S CONNECTION TO OVERALL HEALTH WILL BE RECOGNIZED

December 31st, 2007

Title: ED’S CONNECTION TO OVERALL HEALTH WILL BE RECOGNIZED ,  By: Mulcahy, John J., Urology Times, 00939722, Feb2000, Vol. 28, Issue 2

Section: Focus 2000

Erectile Dysfunction

Advances in the last 25 years in the diagnosis and treatment of erectile dysfunction (ED) have been monumental. As recently as 1973, when the penile implant was introduced, no effective treatment existed for organic impotence . Since then, less invasive treatments have arrived on the scene, and more patients have sought treatment. The arrival of sildenafil 2 years ago has greatly increased awareness that ED is a major problem affecting an estimated 25% of the population.

What do the next 25 years hold? As with the rest of medicine, the future for the treatment of ED looks very positive.

• ED-ucation. Education of primary care physicians on both the diagnosis and treatment of ED and their ability to establish a comfortable interplay with patients on this subject will hopefully progress in the next decade.

Currently, most primary care physicians, although usually the first clinician a patient sees for this condition, not only need education in the diagnosis and treatment of ED but also guidance in appropriately addressing the subject with their patients. Many are unfamiliar with how to inquire about erectile dysfunction using a sexual history, for example. Serious efforts will be made to achieve the goal of improved physician education now that ED has been recognized as a serious medical condition.

  • Oral medications. Oral medications, specifically the phosphodiesterase inhibitors, have supplanted in popularity more aggressive and invasive medical and mechanical treatments for this malady. New oral compounds under development will hopefully have fewer side effects, better tolerance, and more effective applications in patients with a broader range of etiologies. Becuase it is doubtful that all patients will respond to oral medications, injectable medications and mechanical devices will continue to be necessary, although in a smaller percentage of patients.
  • Perfected implants. For patients with a scarred penis and those who fail medical treatment, penile implants have been and will continue to be a satisfactory and successful treatment option. The current models have been perfected with very good mechanical reliability. Few refinements have been seen in the last 10 years. Repair rates seen with penile implants, when properly placed, are now some of the lowest among mechanical products of any type.
  • ED’s connection to overall health. Recognition of erectile dysfunction as a detriment to overall health will become more widely accepted. Testimony from patients with ED who have experienced depression and other medical problems and then received effective treatment will support the premise that the successful treatment of ED will correct many other physical and psychological problems in the same patient. When depression is relieved, compliance with medical regimens for other disease processes has been shown to improve.
  • Gene therapy and tissue reconstruction. In other areas of medicine, gene therapy, angiogenesis, and tissue regeneration have seen rapid development and promising directions. Their application to erectile dysfunction is underway, and we hope to see very positive advances in these areas within a number of years. Use of this technology may result in restoration of erections without the need for medications or technical devices.

PHOTO (COLOR): Dr. Mulcahy

~~~~~~~~

By John J. Mulcahy, MD, INDIANA UNIVERSITY MEDICAL CENTER

Adapted by MD, INDIANA UNIVERSITY MEDICAL CENTER

John J. Mulcahy, MD, a member of the Urology Times editorial council, is professor of urology, Indiana University Medical Center, Indianapolis.


Copyright of Urology Times is the property of Advanstar Communications Inc. and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Urology Times, Feb2000, Vol. 28 Issue 2, p17, 1p

LIBIDO: FACTS AND FANTASY

December 31st, 2007

Title: LIBIDO: FACTS AND FANTASY ,  By: Ahmed, Aftab J., Total Health, 02746743, Sep/Oct2001, Vol. 23, Issue 5


With the exception of prolonging life, nothing has fascinated, intrigued and indeed mystified man more than the fantasy of enhancing his sexual prowess. Human history is rife with the symbolisms of sexuality and fecundity and the list of pills, lotions and potions to stimulate libido is long and tired. It is only in the recent past, however, that the basic mechanisms have been elucidated, which have allowed us to address the issue of libido and in fact sexual dysfunction per se more rationally. Sexual dysfunction is an umbrella term that encompasses an array of conditions that afflict both genders. Of these, erectile dysfunction (ED) is the condition most exhaustively covered by the mass media–thanks in no small part to the willingness of the ex-senator Bob Dole to bring ED out of the closet, as it were. The “courage” shown by Mr. Dole is largely responsible for mature emphasis on, and awareness of, sexual health.

Erectile dysfunction is the dreaded word that can change lives for good and exact a heavy emotional price. To the sufferers of ED, it is most disconcerting that it sneaks up over the years and is hardly discernible. Its underlying cause may just as well be psychological as organic or physical. Conservative estimates are that roughly 150 million men suffer from ED worldwide, particularly those over the age of 60.

What is ED, or impotence, and how does it ensue? Essentially ED is the inability to attain or sustain penile engorgement necessary for normal coitus and could be either primary or secondary. Primary ED, which is quite rare, is indicative of severe psychopathology; in secondary ED, on the other hand, the coitus cannot be successfully completed, despite initial engorgement. In rare cases, biogenic factors such as low testosterone and disorders of hypothalamic-pituitary-gonadal axis complicate the presentation of primary ED. In secondary ED, approximately 70 percent of cases are psychological that include guilt, fear of intimacy or depression.

The mechanisms that contribute to ED are numerous and complex (see sidebar) and may be presented either concurrently or sequentially.(n1) A cursory look at the flow sheet shows that any one of the steps involved may precipitate and/or aggravate ED. It also suggests that the erectile process is so tightly orchestrated that, in turn, is controlled by a number of biochemical steps. Thus the ineffable “mind-set” for an intimate encounter is central to sustained engorgement of the penile tissue. It is for this reason that in the early stages of marketing Viagra, Pfizer’s direct-to-consumer advertisement blitz forcefully underscored the importance of romantic context in its efficacy. The requisite context stimulates nerves, which begin to fire and, ultimately, initiate the cascade of reactions that cause penile tumescence (swelling).

Whereas the hydraulic physiology of the erectile process was discerned much earlier than the biochemical steps involved, it is only recently that the role of blood flow has been fully understood. This was impelled by the recognition that the erectile process is not a result of muscle contractions and relaxation but is due to blood engorgement. The more the blood flows through the male reproductive organ (MRO), the firmer the penile engorgement. The “gatekeepers” for the blood flow are smooth muscle cells in the spongy tissue of MRO. When smooth muscles are constricted, the blood flow is restricted to a trickle–not unlike squeezing a garden hose. When these same cells relax, however, the blood flows as if the pressure on the hose were released. Consequently, as the blood from the arteries gushes to fill the two expandable reservoirs inside the MRO, called corpus cavernosa, rigid and sustained tumescence results.

What triggers the blood to fill corpus cavernosa? In the early 1990s it was demonstrated that in healthy individuals blood flow is triggered when nerve endings release nitric oxide (NO), a relatively short-lived neurotransmitter, which is the same substance that relaxes smooth muscle cells as well.(n2) Quickly thereafter it was found that NO initiates the cascade of reactions to engorge the MRO and cause tumescence. Briefly, nerves in the pelvic area respond to stimuli from the brain to produce NO, which dilates the blood vessels throughout the region to supply blood for engorgement. Since NO is indispensable in this process, it was logical to investigate whether its decreased amounts contributed to ED. Indeed, it turned out that nitric oxide synthase, the enzyme that produces NO, is the culprit in impotence. It should be noted that aging alone does not necessarily precipitate impotence. Attendant organic problemsmay suppress the release of NO and contribute to ED.

In light of the foregoing, increase in the blood flow would be expected to stimulate libido. Parenthetically, this holds true not only for men but also for women. Interestingly, research on sleep has provided evidence that women undergo similar changes in blood flow to the pelvic floor muscle during sleep cycle as do men. Thus a healthy libidinal response depends on well-functioning vasculature in the urogenital arteries. It is precisely for this reason that clinical trials are underway to evaluate the efficacy of Viagra on female libidinal response.

While Viagra has become a market dynamo in amelioration of ED, its mode of action is inhibitory rather than stimulatory. This may explain, at least partially, the side effects of Viagra, even though it works almost immediately. For obvious reasons, two pharmaceutical houses have Viagra-like drugs in preparation. Quite plausibly, Viagra’s side effects will be recapitulated in these new remedies as well. It is for concerns such as these that the so-called “Viagra refugees” are clamoring for natural alternatives to boost libido.

There are “natural solutions” galore that claim to restore sexual function overnight as if by magic. In fact, in the fray of the cluttered market place of Viagra alternatives, it is difficult not to be taken by the unabashed enthusiasm and indeed, unqualified promises of a carnal Shangri-la. Thus it is difficult to differentiate products that have a fighting chance to alleviate the symptoms of ED from those with non-validated claims. For example, inasmuch as testosterone replenishment may help resolve sexual dysfunction, it is a viable option only under competent clinical supervision. Likewise, numerous herbs have been positioned to mitigate, if not outright reverse, ED symptoms. While circumstantial evidence does suggest that some of the herbs could help attenuate the severity of ED over extended periods of time, it should be noted that these are “preventive” modalities at best. That is, they are likely to be effective only if used over the long haul as part of a disciplined nutritional regimen. In other words, contrary to the received opinion, there are no quick fixes unless, of course, the underlying problem is adequately addressed.

Erectile dysfunction is a chronic condition which takes decades to develop. As such, a systemic approach in its management is a more realistic alternative. Since blood flow to the erectile tissue is the critical factor, substances that enhance circulation should mitigate ED. Citrulline, a relatively specialized amino acid in the body, is the precursor that optimizes blood flow by “pacing” the vas culature.(n3) Mechanistically, citrulline is converted to Loarginine, which is a known inducer of NO. (Fig. 1) Thus by inducing the body’s own vasodilator, citrulline ensures blood flow in sufficient amounts to the pelvic floor to engorge the erectile tissue.

Since citrulline increases NO levels via arginine, the question is forced whether arginine might not be a more obvious alternative. Not so, for arginine is less prone to be absorbed efficiently to induce NO. After all, it has to compete with a surfeit of amino acids for the same transporters in the intestinal wall to enter the bloodstream. In contrast, the relative rarity of citrulline facilitates its more ready transport across the intestinal wall. Importantly, oral intake of citrulline more effectively produces arginine in situ to generate NO.(n4) Put differently, citrulline increases the plasma levels of induced arginine better than orally ingested arginine. How so? Arginine is assimilated over the digestive tract and upon entering hepatic circulation, the bulk of it is degraded. In contrast, citrulline is not cleared by the liver, rather, it is taken up by the kidney and other tissues where it is converted to arginine. Specifically, oral intake of citrulline results in 60 percent increase in the plasma levels of arginine. (Fig. 2) It is significant that citrulline sustains plasma arginine levels much longer titan intake of a similar dose of arginine supplementation.(n5)

By increasing the blood flow, citrulline tweaks the body’s repair kit to reduce the severity of ED presentation, which should recharge the libido for a revitalized life. Hence, citrulline provides a more rational approach toward sexual dysfunction, which stands in stark relief to much-touted aphrodisiacs with exaggerated claims. Named after Aphrodite, the Greek goddess of beauty and physical love, these supposed stimulants range from anchovies to adrenalin, licorice to lard, scallops to Spanish fly and everything in between. Aphrodisiacs fan the fantasy of unlimited, even insatiable, libido. Such fantasy, however enticing, militates against not only human physiology but also the alleged functions of a multitude of aphrodisiacs. Therefore, a systemic modality that helps correct the underlying problem is a more meaningful means to restore vitality and robustness. In that regard, citrulline is not an aphrodisiac but is much more that over time could potentially rejuvenate the zest for life. Equally, by promoting circulation through the highways and byways of the cardiovascular tree, citrulline fosters better health, which is indispensable for a healthy libido.


THE MALE ERECTILE PROCESS

Step 1: Sexual stimulation causes a variety of nerves originating in the brain to start firing.

Step 2: Once stimulated, these nerves release the neurotransmitter acetylcholine in the penis.

Step 3: Acetylcholine, in turn, causes the endothelial cells in the penile arteries to begin producing NO by the action of a specific enzyme called nitric oxide synthase.

Step 4: Once produced, NO triggers the release of another chemical cyclic guanosine monophosphate (cGMP), Cyclic GMP is one of the many potent vasodilators found in the human body.

Step 5: As cGMP levels increase, the smooth muscles of the penile arteries relax, the vessels dilate, and increase blood flow causes tumescence of corpus cavernosa, producing an erection.

Step 6: Even as NO continues to generate cGMP, another enzyme begins to break it down. This enzyme, known as phosphodiesterase, functions like a brake on the entire cascade from becoming excessive or permanent (priapism). Priapism can cause permanent damage to erectile tissue.

Step 7: Following climax, or cessation of sexual stimulation, the nerves stop firing and the nerve endings stop releasing acetylcholine. In the absence of acetylcholine, the endothelial cells stop NO production, without which no cGMP can be produced. The residual cGMP is degraded by phosphodiesterate. The net result is that smooth muscles once again contract as the penile tissue goes back to its non-aroused, flaccid state.

This flow sheet demonstrates how easily this balance of steps in the erectile process can be affected at any step and how erectile dysfunction could ensue. Importantly, it also suggests that increased production of NO can enhance libido.

DIAGRAM: Figure 1: The Citrulline-Nitric Oxide Cycle.

GRAPH: Figure 2: Oral Citrulline vs. Plasma Arginine


References

(n1))
McConnell, J. and Wilson, J. “Impotence,” In Harrison’s Principles of Internal Medicine, Isselbacher et al., Eds. McGraw-Hill, Inc., New York, New York, 1998, p. 263 ff.

(n2))
Burnett, A. “Nitric Oxide in the Penis: Physiology and Pathology,” J. Urology: 157, 320, 1997.

(n3))
Waugh, W., Daeschner, W., Files, B, McConnel, M. and Strandjord, S. “Oral Citrulline as Arginine Precursor,” J. Nat. Med. Assoc., in press, 2001.

(n4))
Windmueller, H. and Spaeth, A. “Source and Fate of Circulating Citrulline,” Am. J. Physio.: 241, E473, 1981.

(n5))
Waugh, W. “Orthomolecular Medical Use of L-Citrulline for Vasoprotection, Relaxative Smooth Muscle Tone and Cell Protection,” United States Patent No. 5 874 471, 1999.

~~~~~~~~

By Aftab J. Ahmed, Ph.D.

Aftab J. Ahmed, Ph.D. is director research and development and business development. Marlyn Nutraceuticals, Inc. E-mail: aftabahmed@msm.com


Copyright of Total Health is the property of Total Health Holdings LLC. and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Total Health, Sep/Oct2001, Vol. 23 Issue 5, p46, 2p

VIAGRA WITH A VENGEANCE

December 31st, 2007

Title: VIAGRA WITH A VENGEANCE ,  By: Kurlantzick, Joshua, Insight on the News, 10514880, 03/06/2000, Vol. 16, Issue 9

The widespread use Of Viagra by the sex tourists of Thailand’s seedy nightlife scene has turned deadly. Bangkok hospitals and embassies estimate that at least 100 male tourists who died in the country last year succumbed from heart attacks, strokes or other illnesses linked to the use of the popular anti-impotency drug.

Bangkok long has been a center for prostitution and a popular destination for male travelers, who account for nearly three-quarters of all visitors to the country. Sex tourism decreased in the early 1990s due to the fear of HIV/AIDS. But Pfizer’s pharmaceutical phenomenon has contributed to a recent revival of Thailand’s sex industry.

Thai doctors and pharmacists prescribe genuine Viagra, but black-market copies of the drug are widely available at brothels in the rod-light district and even at some respectable drugstores. The black-market pills may be responsible for a majority of the fatalities. Customers have no way of knowing either what these copies contain or how their ingredients affect a person engaged in physical activity.

Diplomats complain that Viagra-related deaths strain not only hospital staffs but also embassy resources. An inordinate amount of documentation and special sensitivity is required when arranging funerals for men or when sending the bodies home, notes a secretary of consular and legal affairs at the German Embassy, Physicians and embassy staff sometimes omit mention of Viagra or of prostitution in autopsies and letters to next of kin.

Reports of visitors’ deaths have not slowed Thailand’s rapidly expanding tourism industry, which is the country’s largest source of foreign exchange. Tourist arrivals to Thailand grew by 11 percent during the July-September quarter of 1999, despite fatalities caused by sexual overexertion, road accidents, murders and dangerous animals. A total of 153 tourists died in motorcycle accidents on the Thai resort island of Phuket in 1999, crime against foreigners rose roughly 10 percent and a German tourist bled to death after being attacked by an unidentified sea creature.

~~~~~~~~

By Joshua Kurlantzick


Copyright of Insight on the News is the property of Washington Times Corporation and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Insight on the News, 03/06/2000, Vol. 16 Issue 9, p30, 1p

FACILITATING SEXUAL HEALTH: INTIMACY ENHANCEMENT TECHNIQUES FOR SEXUAL DYSFUNCTION

December 31st, 2007

Title: FACILITATING SEXUAL HEALTH: INTIMACY ENHANCEMENT TECHNIQUES FOR SEXUAL DYSFUNCTION ,  By: Southern, Stephen, Journal of Mental Health Counseling, 10402861, Jan99, Vol. 21, Issue 1


Technological advances afford opportunities for reclaiming sexual functioning, even among individuals with chronic illness or devastating injury. However, medical advances cannot insure that sexual outlet will facilitate intimacy in a committed relationship. Sex therapy, based on the pioneering work of Masters and Johnson, addresses dysfunction in an essential relational context. This article provides an overview of treatment strategies for promoting sexual health.

As we move toward the 21st century, technological advances afford opportunities for nearly everyone to enjoy a satisfying sex life. For example, individuals with devastating spinal cord injuries can learn to reclaim the experience of orgasm, which can be verified by PET and MRI findings, even in the absence of genital sensation (Whipple, Gerdes, & Komisaruk, 1996). Recently, the introduction of an oral medication for erectile dysfunction (sildenafil citrate or viagra ) provided hope for thousands of men and their partners, yet catalyzed the recurrent debate regarding the benefits and limitations of a quick fix for sexual problems (Bancroft, 1990; Tiefer, 1986). Breakthroughs in technology and advances in medicine cannot insure that sexual outlet will facilitate intimacy in a committed relationship.


SEX IS A NATURAL FUNCTION

This statement represents the cornerstone of sex therapy pioneered at Masters & Johnson Institute. The goal of any effective treatment of sexual dysfunction involves removing the roadblocks to the natural expression of sexuality within an intimate relationship. These roadblocks may be organic or psychogenic. Yet, ultimately, sexual health should be defined in the context of facilitating intimacy in an ongoing relationship.

Intimacy is a core component of love. The word intimacy has depth in its very meaning. It was originally derived from the Latin intimus meaning “inner” or “inmost.” The French intime signifies “deep, fervent, ardent.” The Italian intimo means “close” or “innermost.” The derivation of intimacy indicates there is an internal, emotional experience by which each partner is drawn close to the other. Sexual intercourse is a powerful symbol of the loving embrace of intimacy.

When individuals experience difficulty in sexual functioning, they tend to avoid opportunities for physical and emotional closeness (McCarthy, 1997; Moret, Glaser, Page, & Bergeron, 1998). Sex therapy techniques can be used not only to remove roadblocks linked to specific sexual disorders, but also to strengthen intimacy in committed relationships. Although the “medicalization” of sexual dysfunction treatment has resulted in underemphasis of dyadic issues (Ackerman & Carey, 1995; Tiefer, 1986), classic models of sex therapy (e.g., Kaplan, 1979; Masters & Johnson, 1970) and more contemporary approaches (Barbach, 1997; Rosen & Leiblum, 1995; Schnarch, 1997; Schwartz & Masters, 1988) focus on the centrality of couple intimacy enhancement. In the case of erectile dysfunction, sex therapy outcome has been associated with improvement in dyadic communication, expression of affection, and support for partner adjustment (Hawton, Catalan & Fagg, 1992).

The purpose of this article is to provide a brief overview of intimacy enhancing treatment approaches for selected sexual dysfunctions. Some attention is devoted to recent advances in sexual medicine. However, the present overview is offered to counterbalance the medicalization of sexual health by emphasizing the importance of relational intimacy in disrupting syndromes of sexual dysfunction.


TYPES OF SEXUAL DYSFUNCTION

If intimacy is the goal of sexual health, then the relationship is the major unit of analysis in the assessment or treatment of sexual dysfunction (Hirst & Watson, 1997; McCabe, 1997; Masters & Johnson, 1970). In the 1970s, when the profession of sex therapy was growing rapidly in acceptance, roadblocks to natural sexual functioning were viewed almost exclusively as emotional or relational in nature. Ninety percent of sexual dysfunction cases were treated as psychogenic in origin (Kaplan, 1983; Wincze & Carey, 1991). Today, etiology in most cases is determined to be organic, primarily because enhanced technology permits the identification of subtle anatomical and physiological features It is likely that almost all cases of sexual dysfunction involve mixed etiology with psychogenic and organic factors (Burvat, Burvat-Herbaut, Lemaire, Marcolin, & Quittelier, 1990; Kaplan, 1983; Kellett, 1995). Although medical treatments are available, they do not necessarily address psychogenic factors or automatically contribute to intimacy. Thus, sex therapy remains an important component in the assessment and treatment of sexual dysfunction in men and women.

Assessment of sexual dysfunction involves ideally a treatment team committed to facilitating sexual health in an intimate relationship. Sexual medicine clinics (Kellett, 1995; Melman, Tiefer, & Pedersen, 1988; Renshaw, 1988; Verma, Khaitan, & Singh, 1998) include physicians and mental health professionals who possess specialized training and experience in the diagnosis and treatment of sexual problems. According to the sexual health model, there are two domains of assessment–the individual and the relationship (McCabe & Cobain, 1998). Some cases of sexual dysfunction seem to be related primarily to individual factors (e.g., vascular erectile dysfunction), while other cases are clearly relational in nature (e.g., sexual desire discrepancy). There are emotional and biological features among the many individual and relational factors in sexual dysfunction.

Comprehensive evaluation of sexual dysfunction can be tailored to the presenting problem. Particular disorders for males and females exist in each of the phases of the sexual response cycle, which consists of desire, arousal, orgasm, and resolution.

The types of dysfunction identified in the table include some conditions described in the Diagnostic and Statistical Manual of Mental Disorders (4th ed.) (American Psychiatric Association, 1994). The table includes some types or classifications recognized in clinical sexology practice (e.g., Kaplan, 1983; Wincze & Carey, 1991). The various dysfunctions may be considered either primary (lifelong) or secondary (reflecting an acquired problem often caused by another condition). In addition, some of the types are generalized, occurring across sexual situations and partners, or situational, applying only to particular settings or partners.

Each of the types of sexual dysfunction has specific diagnostic criteria. The types can be briefly described as follows. Hypoactive sexual desire refers to persistent or recurrent lack of sexual fantasy or desire for sexual activity. Sexual aversion includes persistent or recurrent avoidance of sexual outlet due to distress associated with potentially sexual stimuli. In some relationships, there is a significant difference in desire for sexual outlet, leading to frustration or discomfort for one or both partners. Sexual desire discrepancy is encountered frequently in marital and sex therapy (Beck, 1995; Kaplan, 1979; Lobitz & Lobitz, 1996; MacPhee, Johnson, & van der Veer, 1995; Schwartz & Masters, 1988; Southern, 1985).

Sexual compulsivity is a term coined by the Masters & Johnson Institute to account for hyperactive sexual fantasy and behavior, which produces adverse physical, emotional, and social consequences (Carnes, 1983, 1996; Cooper, 1998; Schwartz, 1996). The general domain of sexual compulsivity may contain paraphilias, or conditions in which sexual interest and preferred or exclusive sexual outlet is associated with a variant or unusual object, partner, or activity (e.g., cross-dressing or transvestic fetishism) (Abel & Osborn, 1992; Abel & Roleau, 1995; American Psychiatric Association, 1994; Moser, 1992). Any of the desire phase disorders can interfere with pursuit of intimate, partner-oriented sexual expression.

Erectile dysfunction includes a number of conditions in which there is difficulty attaining or maintaining sufficient erection (e.g., 70% of full erection) for penetration. The rigidity of erection varies significantly over time and may be affected by a number of situational and chronic conditions. Thus, it is useful to relate the condition to inability or difficulty in completing satisfying intercourse. There are hormonal, neurological, and vascular causes of erectile dysfunction (Burvat et al., 1990; Rowland & Slob, 1995). In addition, performance anxiety and “spectatoring,” or becoming a worried observer of sexual functioning, contribute significantly in the etiology of erectile dysfunction. This condition has been called impotence, a term with many negative and shameful connotations. Sexual arousal disorder occurs in the female when there is difficulty with lubrication or vasocongestion of the labia and clitoris. Similar to erectile dysfunction, female sexual arousal disorder may be associated with hormonal, vascular, and neurological conditions (Palace, 1995; Read, 1995). Labels such as “impotence” and “frigidity” are seldom used in professional settings; however, they are still in common usage in the general public.

Orgasm phase disorders are caused by organic and psychogenic factors. Problems with orgasm (including retrograde ejaculation in which semen is directed into the bladder rather than the urethra) may be secondary to diabetes. Inhibition of orgasm is a side effect of some medications, especially Prozac (fluoxetine hydrochloride) and other serotonin reuptake inhibitors (Ashton, Hamer, & Rosen, 1997; Seagraves, 1998). While arousal phase disorders are linked primarily to stress and anxiety, disorders of orgasm can be conceptualized as difficulty in “letting go” or facilitating the pleasurable sensations of the plateau stage of arousal. Orgasm is a reflex that will occur after an individually determined level of mental and physical stimulation. Individuals who try to maintain excessive control over the environment may have trouble experiencing orgasm (Anderson & Cyranowski, 1995; Byrne & Schulte, 1990; Heiman & LoPiccolo, 1988; Rosen & Leiblum, 1995).

Delayed ejaculation refers to difficulty in attaining orgasm, especially in the context of partner-oriented sexual activity (Apfelbaum, 1989). Some males have never experienced a climax (i.e., ejaculatory incompetence). Other males believe that they climax too quickly. The determination of rapid ejaculation (usually called “premature ejaculation”) almost always involves subjective estimates from the male and his partner about the desired duration of intercourse. Thus, relational factors play a critical role in the assessment and treatment of this dysfunction (McCarthy, 1994; Spector & Carey, 1990).

Only 40% to 50% of females are regularly orgasmic during intercourse (Masters & Johnson, 1970). The “missionary position” or “male superior” position seems to be ill-suited for stimulating the female. Many women are at least situationally anorgasmic, depending upon certain setting and partner variables. If a woman has never experienced an orgasm by any means, then she may have inhibited female orgasm. The current popular term for the condition is “preorgasmic,” suggesting that every woman has the right to realize this natural sexual function (Heiman & LoPiccolo, 1988).

Few classification systems include resolution phase disorders. Yet, if sexual compulsivity is accepted as a valid dysfunction, then it is clear that this condition extends into the resolution phase of the sexual response cycle. Ordinarily, when a male experiences ejaculation, he loses much of his erection and additional stimulation of the penis is considered neutral or aversive. Masters and Johnson (1966,1970) described the refractory period in which there is a gradually increasing period of time (or latency) between the last climax and arousability or interest in another sexual outlet. While females have the potential for multiple orgasms, in general, there is an identifiable period of time in which additional stimulation is not wanted.

The resolution period is also important in terms of bonding or attachment between loving partners (Anderson & Cyranowski, 1995; Lobitz & Lobitz, 1996). According to the sexual health model advocated in this article, in which intimacy is the primary goal, the resolution phase affords opportunity for sharing physical and emotional closeness, warm communication, and mutual respect. Whenever sex is mechanical, compulsive, or abusive, there is no intimacy. For example, the resolution of sexual intercourse may feel like one partner has used the other for masturbation. Sexual health should take into consideration the emotional components of loving partners. Intimacy dysfunction refers to a class of conditions in which sex is solitary, compulsive, or abusive to oneself or one’s partner.

Pain may occur at any point in the sexual response cycle. Obviously, pain is incompatible with pleasure and intimacy in the ongoing sexual experience. Dyspareunia occurs in both males and females. The condition is associated with pain or discomfort in the genitals, which may be a function of organic or psychogenic factors (Meana & Binik, 1994; Steege & Ling, 1993). A related conditions in females, vaginismus, involves involuntary contraction of the circumvaginal muscles such that penetration is difficult or impossible. (Read, 1995). Vaginismus is encountered among survivors of sexual abuse (Leiblum, Pervin, & Campbell, 1989). In fact, much sexual dysfunction in males and females can be related to neglect or abuse in childhood, including lack of sex information, sex negative attitudes, and poor family boundaries (Kinzl, Mangwerth, Traweger, & Biebl, 1996; Kinzl, Traweger, & Biebl, 1995; Sarwer & Durlak, 1996; Wilsnack, Vogeltanz, Klassen, & Harris, 1997).

As individuals learn more about natural sexual functioning, they are able to make sexual choices that foster intimacy in committed relationships. Advances in medical treatment and technology afford opportunities for all couples to realize sexual fulfillment. When there are difficulties in sexual functioning, a comprehensive evaluation, including input from both partners, is indicated. Physicians should complete a history and physical examination, including laboratory testing as indicated, to rule out disease states and medication side effects in the pathogenesis of sexual dysfunction (Kaplan, 1983; Morley & Kaiser, 1993). Urologists and gynecologists are trained generally to address male and female sexual complaints, respectively. In recent years, some physicians have devoted themselves to specialty practice in sexual medicine (Kellett, 1995; Melman et al., 1988; Verma, Khaitan, & Singh, 1998). Mental health professionals who have specialized training in sexual health are equipped to complete an assessment tailored to the particular presenting problem and the dyadic issues of the couple (Ackerman & Carey, 1995; Rosen & Leiblum, 1995; Wincze & Carey, 1991). A treatment plan that addresses organic and psychogenic etiology, including individual and relational factors, can be constructed.


TREATMENT OF SEXUAL DYSFUNCTION

Masters and Johnson (1966,1970) demystified sexual functioning and encouraged couples to seek help. Before 1970, sexual dysfunction was treated by psychiatrists and mental health professionals as symptoms of underlying emotional problems. Today, sex therapists from many disciplines, who have specialized training in the assessment and treatment of sexual problems, offer interventions which remove roadblocks to the natural expression of sexuality in an intimate relationship.

Masters and Johnson began in 1959 their revolutionary program for treating sexual problems. They worked only with couples (originally “the marital unit”) because each case of sexual dysfunction was considered relational in nature. They found that roadblocks to natural sexual functioning were primarily psychosocial (Masters & Johnson, 1970).

With advances in technology, it is clear that organic factors are frequently involved in the etiology of sexual dysfunction (Feldman, Goldstein, Hatzichristou, Krane, & McKinley, 1994; Palace, 1995). For example, vascular problems are major contributors to erectile dysfunction (Burvat et al., 1990; Rowland & Slob, 1995). However, the pioneering model of Masters and Johnson Institute never focused of the causes of individual problems. Rather, the male and female co-therapy team worked with couples to help them overcome relational and emotional roadblocks to intimacy. When intimacy is restored, the natural sexual response is facilitated. In addition, Masters and Johnson offered specific homework exercises to address particular concerns in the sexual response cycle, especially problems arising during arousal or orgasm.

The Masters and Johnson (1970) model for sex therapy involves intensive treatment of couples experiencing sexual dysfunction. Ideally, treatment is offered daily by the co-therapy team over a 2-week period (usually 10 to 12 days). Daily continuity and removal from typical distractions of work and home set the stage for optimal progress. Nevertheless, variations on the Masters and Johnson model include the “weekend intensive” and once weekly outpatient visits. The efficacy of the therapy decreases with changes from the original model, however (Masters & Johnson, 1970; Schwartz & Masters, 1988).

Although the Masters and Johnson model prescribes homework for particular types of sexual dysfunction, there are several common interventions without regard to the specific presenting problem. Initially, the couple is asked to refrain from sexual outlet. This “authoritative pronouncement” (Masters & Johnson, 1970, pp. 287-290) enables the couple to focus on intimate communication without the demand to be sexual. Another common intervention involves the “roundtable” (Masters & Johnson, 1970, pp. 57-78), in which the results of assessment are discussed and sex education is provided. The next step in intensive treatment incorporates one of the most famous interventions in the Masters and Johnson model, “sensate focus” (Masters & Johnson, 1970, pp. 66-85).

Sensate focus encourages concentration on the subtle sensations involved in intimate, nonsexual contact. Initially, the breasts and genitals are “off-limits,” fostering a sensual experience without preoccupation with sexual performance. Each partner takes turns, engaging in “selfish touching,” which is touch guided by one’s interests rather than trying to do anything to or for one’s partner. If the partner feels any discomfort or wishes to redirect the one doing the touching, then that person places his or her hand on top the partner’s hand. This “handriding” is a tool, like other techniques in the Masters and Johnson model, for realizing sexual self-responsibility. Various components of the sensate focus homework address roadblocks having to do with sexual demand, performance pressure, and “spectatoring,” or becoming an anxious observer rather than a participant in sexual functioning.

While Masters & Johnson (1970,pp. 342-360) reported success rates as high as 97% for rapid ejaculation and 80% across all male and female sexual dysfunctions, their model and research have been criticized (Reynolds, 1977; Tiefer, 1991; Zilbergeld & Evans, 1980). However, the Masters and Johnson Institute model (Masters & Johnson, 1970; Schwartz & Masters, 1988) has been for decades the guiding conceptual and clinical paradigm in sex therapy (Rosen & Leiblum, 1995). The core components of sex therapy, including nondemand sexual pleasuring, have been supported in several studies (Hawton et al., 1992; Hirst & Watson, 1997; Rosen & Leiblum, 1995; Sarwer & Durlak, 1997; Wylie, 1997).

Overall, increasing comfort and pleasure relax away anxiety previously conditioned over many frustrating sexual experiences. The sensate focus exercises, which move from nongenital exploration to nondemand sexual outlet through touch, provide opportunities to reclaim open communication and sensuality. Consultation with the couple includes recommendations for rekindling romance and enjoying intimacy.


INTERVENTIONS FOR SPECIFIC DYSFUNCTIONS

With the completion of sensate focus exercises, the couple is ready to pursue techniques targeted at specific forms of sexual dysfunction. Using the classification scheme constructed for this article (see Table), it is possible to describe some specific interventions for selected sexual dysfunctions according to phases in the sexual response cycle.


Hypoactive Sexual Desire

Hypoactive sexual desire (HSD) involves recurrent lack of sexual fantasy or interest in sexual activity. Although HSD occurs in both males and females, women most often present this dysfunction (Anderson & Cyranowski, 1995; Beck, 1995). HSD may be primary, in which a person never developed an interest in sex, or secondary to other problems or concerns. The condition may be pervasive and generalized or situational, relating only to particular partners, settings, or activities. For example, an individual may experience lack of desire for one’s partner due to suppressed anger and chronic marital discord, yet retain some sexual desire for an idyllic encounter with another person. Similarly, individuals who have atypical, especially nonpartner-oriented preferences (e.g., a paraphilia such as fetishism) may have a marked disinterest in sex with one’s available spouse (Moser, 1992). HSD must also be differentiated from medical conditions such as endocrine problems and mental disorders, including depression (Kaplan, 1979; 1983).

Following a careful differential diagnosis, it is possible to tailor treatment to the needs of the particular person. Whenever possible the partner should be included in the intervention because of the obvious relational antecedents and consequences in HSD (Heiman, Epps, & Ellis, 1995; MacPhee et al., 1995). In the typical presentation, a woman develops HSD after a long period of marital dissatisfaction. She may feel unsupported and misunderstood. Often her husband persists in making sexual demands, although they have little communication and genuine intimacy. She cannot emotionally say “Yes!” to sex because she is unable to say “No.” Her HSD develops in response to suppressed or unexpressed anger in the context of the power imbalance in the marriage (Schwartz & Masters, 1988; Southern, 1985).

Treatment involves communication and negotiation skills training for the couple (including “I language” assertion, originally developed by Virginia Johnson); sensate focus, to remove the demand for sexual outlet; and encouragement of sexual self-responsibility, by focusing upon the woman’s preferences for the marital sexual relationship (Masters & Johnson, 1970). In the more complicated cases of primary HSD, the woman will likely need a period of individual consultation to learn about sex and acquire the ability to fantasize and associate pleasure with erotic cues and sensations. In some cases, testosterone, the male sex hormone, may be prescribed to increase the female’s level of desire (Beck, 1995).


Erectile Dysfunction

Erectile dysfunction is the most common sexual problem presented in sexual medicine clinics (Kellett, 1995; Melman et al., 1988). Yet, the problem has likely persisted for some time before the anxious, performance-oriented male “acknowledges his failure” and seeks help. Sexual dysfunction and other problems of daily life are often maintained by the words and images used to describe the difficulty. The “impotent” male who has lost his masculine power becomes preoccupied with the normal variations in penile tumescence. By focusing on slight losses of erection and anticipating a “failure,” he strengthens irrational expectations and contributes to increasing anxiety, which steals the blood flow to the penis. While many cases of erectile dysfunction include organic factors (e.g., vascular disease), the syndrome of increasing performance pressure and anxious self-observation contributes significantly to the couple’s distress and avoidance (McCarthy, 1997; Masters & Johnson, 1970).

Interventions for erectile dysfunction usually include some attention to the cognitive distortions and negative self-evaluations that maintain sexual dysfunction. While it may come as a surprise to some individuals, an erect penis is not a requirement for satisfying sex. Zilbergeld (1978) delineated the “myths of male sexuality,” which are based on a hypermasculine, fantasy model of sexuality which constrains both partners. The myths that a man must orchestrate sex in which he is “hard as steel” and “lasts all night” contribute to erectile dysfunction. The initial steps in treatment for this problem include education about limitations of stereotypical gender roles and disputation of irrational beliefs concerning sexuality (Barbach, 1997; McCarthy, 1994, 1997; Zilbergeld, 1978).

Sex therapy for erectile dysfunction builds on the relaxing experience of sensate focus. By the third set of sensate focus exercises, the couple has learned that satisfying sexual outlet can be realized through genital touching in an intimate, romantic context. An erection is not needed for sexual satisfaction. Gradually, the focus is shifted to containment of the soft penis in the vagina, followed by gentle thrusting of the penis with the female astride. The therapeutic exercises are graduated to desensitize conditioned anxiety and promote sense of hope or accomplishment (Masters & Johnson, 1970).

There are several other methods for treating erectile dysfunction. Medical management includes oral medication (e.g., the long-awaited viagra , or sildenafil citrate, a smooth muscle relaxer), urethral suppository (MUSE or alprostadil), vacuum pump, intracavernosal injection (e.g., Caverject), vascular surgery, and penile prosthesis (Ackerman & Carey, 1995; Morley & Kaiser, 1993). Even herbal treatments such as yohimbine have been used to treat problems with erection (Guirguis, 1998). Mental health treatments include hypnotherapy, relaxation training, strategic or paradoxical intervention, and cognitive-behavior therapy. All of these methods have merit (Ackerman & Carey, 1995; Rosen & Leiblum, 1995). Needs of the particular case identified through a comprehensive assessment should determine the treatment approach. However, each case should be considered relational in nature since the partner is affected or the capacity for partner-oriented intimacy is at risk (Barbach, 1997; Read, 1995).


Rapid Ejaculation

Rapid ejaculation is a sexual dysfunction that is based clearly on relational expectations. The common term, “premature ejaculation” signifies the relational origins of a rapid climax. “Premature ejaculation” indicates that the male has climaxed before producing through intercourse an orgasm for his partner. Obviously, this perspective engenders considerable performance pressure, which in turn potentiates rapid ejaculation. This problem can be solved through a combination of cognitive therapy and therapeutic touching exercises. The intervention is tailored to the severity of the presenting problem (e.g., the most severe case involves ejaculation before intromission) (McCarthy, 1994; Masters & Johnson, 1970; Spector & Carey, 1990; Zilbergeld, 1978).

The couple learns that satisfying sex is not a linear progression from touch (sometimes called “foreplay,” implying a focus on intercourse) to mutual orgasm. Instead, either partner may experience a climax through nondemand pleasuring. In addition, the male’s ejaculation need not terminate the touching opportunity. “Start-stop touching” (also labeled “brinkmanship”) is a major intervention for treating rapid ejaculation (Zilbergeld, 1978). In this method, the male is brought to the point of ejaculatory inevitability through touch during the plateau stage of the sexual response cycle. The partner then stops stimulation, reducing the likelihood of the orgasmic reflex and providing time for the male’s relaxation. Masters and Johnson (1970) recommended the squeeze technique, in which either the corona of the glans penis or the base is squeezed by the partner to delay ejaculation.


Anorgasmia

The treatment of anorgasmia in females has some similarities with therapy for rapid ejaculation(Anderson & Cyranowski, 1995; Masters & Johnson, 1970). In both cases, there is an emphasis upon learning to recognize cues that one is moving through the plateau phase toward orgasm. In addition, individuals are encouraged to relax and assume sexual self-responsibility in touching. The anxiety-provoking demand for orgasm in intercourse is neutralized through sex education and cognitive therapy. Anorgasmia (formerly called “frigidity” in the sexist model that focused on female responsiveness to male initiation) is treated as “preorgasm” in contemporary sexual therapy (Heiman & LoPiccolo, 1988). Every woman has a right to discover and express her unique sexuality, including orgasm when she desires to have one.

Preorgasmic women learn how to facilitate sexual responses through self-touching, fantasy enhancement, and graduated desensitization exercises with a partner (Barbach, 1997; Palace, 1995). Since male-superior (”missionary position”) intercourse is not a optimal form of stimulation for most women, the preorgasmic woman and her partner experiment with other forms of stimulation, such as the use of a vibrator (Heiman & LoPiccolo, 1988). During the individual component of treatment, she is encouraged to “let go,” or experience fully the increasing excitement. One of the interventions for this component is “role play orgasm,” in which the female is asked to simulate a full-body orgasm, sometimes after viewing an instructional videotape. During the couple component of treatment, they are asked to move from sensate focus, through experimentation with various positions and forms of stimulation, to facilitation of orgasm with the partner present. When the woman is able to experience predictably her climax, then a “bridging” technique is enlisted to transfer the potential for orgasm to partner-oriented stimulation during penetration (Barbach, 1997; Heiman & LoPiccolo, 1988; Masters & Johnson, 1970).


Sexual Compulsivity

The last two types of sexual dysfunction, sexual compulsivity and vaginismus, represent relatively rare problems, frequently emerging from untreated sexual abuse trauma (Kinzl et al., 19%; Kinzl et al., 1995; Leiblum et al., 1989).The other types of dysfunction overviewed in the present article need not be caused by any underlying psychodynamics. Sexual compulsivity (also known as “sexual addiction”) is most prominent in males who have suffered sexual abuse or severe disruption of psychosexual development. The developing “lovemaps,” used by victimized males to organize their thoughts and experiences related to eroticism (Money, 1986), tend to exclude intimate, partner-oriented sexual outlet in favor of repetitive, unusual, and exploitative forms of sex. The motivation for sex is not pleasure or sensuality. Rather, the nonsexual functions of sex are exaggerated. Mood altering sexual outlet is used to manage stress, ward off depression, express anger, or bolster a fragile ego (Carnes, 1983,1996; Cooper, 1998; Schwartz, 1996).

Treating sexual compulsivity requires individual and relational interventions designed to disrupt replay of sexual trauma (Schwartz, 1996). In many cases, masturbatory excesses have conditioned variant sexual arousal. By assessing the topography or nature of the sexual arousal pattern through self-report or biofeedback (i.e., penile plethysmography), it is possible to then transfer arousal from unwanted or deviant targets to desired partner-oriented outlet (Abel, Huffman, Warberg, & Holland, 1998). Treatment also involves confronting cognitive distortions, typically in group therapy (Abel, Osborn, Anthony, & Gardos, 1992; Carnes, 1983) Other components in the treatment package involve work with the “sex addict” and the “co-addictive” partner (Schneider & Schneider, 1996). The couple examines boundaries or limits to behavior as well as family-of-origin dynamics that contribute to communication difficulty and intimacy avoidance (e.g., Carries, 1983). Sex therapy interventions are used gradually to increase vulnerability, safety, and security.


Vaginismus

The treatment of vaginismus also emphasizes the intentional facilitation of vulnerability. However, the interventions are primarily behavioral, rather than intrapsychic in nature (Read, 1995; Rosen & Leiblum, 1995). Vaginismus involves the involuntary contraction of the pelvic muscles making penetration difficult, painful, or impossible. The etiology of this condition is psychosocial, primarily in traumatic sexual experiences (Leiblum et al., 1989). Yet, “dyspareunia” or pelvic pain that is untreated conditions vaginismus as the couple continues to suffer through attempts at intercourse (Meana & Binik, 1994). Treatment of vaginismus is a microcosm of the sexual therapy model. The couple abstains from sexual outlet, engages in sensate focus or touching opportunities, learns to associate genital touching with relaxation and pleasure, and desensitizes anxieties associated with demanding, performance-oriented sexual activities. Treating vaginismus usually includes specific desensitization exercises. For example, dilators or digits of increasing circumference are introduced by the female into the vagina. Muscular tension and anxious dread are relaxed away in the safe setting afforded by sexual therapy consultation (Masters & Johnson, 1970; Read, 1995).


viagra AND ERECTILE DYSFUNCTION: PROMISES AND PITFALLS

The emergence of viagra (sildenafil citrate), a simple oral medication for erectile dysfunction, has generated in recent months considerable media attention, making it a good case in point for concluding remarks. viagra produces smooth muscle relaxation and inflow of blood to the corpus cavernosum of the penis, potentiating erection when there is adequate sexual stimulation (Pfizer, 1998). It is less invasive than previous medical interventions such as surgical implantation of a penile prosthesis, injection of medication into the spongy tissue of the penis, or placement of medication via urethral suppository (Ackerman & Carey, 1995; Morley & Kaiser, 1993). Treatment of erectile dysfunction with viagra is reasonably safe, although patients who use nitrates such as nitroglycerine could experience a hypotensive crisis (i.e., dangerously low blood pressure) if they take the medication (Pfizer, 1998).

viagra was well tolerated in clinical trials; however, some men experienced side effects, including headache, upset stomach, visual effects (color tinge), and blurred vision (Pfizer, 1998). The side effects were so mild that few patients decided to discontinue the medication. viagra is effective in producing erections sufficient for sexual activity in 67% to 75% of cases (Pfizer, 1998), an outcome comparable to other medical treatments and sex therapy interventions (Ackerman & Carey, 1995; Guirguis, 1998; Hawton et al., 1992; Masters & Johnson, 1970; Morley & Kaiser, 1993; Rosen & Leiblum, 1995).

Many of the 30 million men in the United States who suffer with erectile dysfunction will benefit from the increasing availability of viagra (Pfizer, 1998). However, viagra is not the “magic pill” or “quick fix” that some will expect or demand (Bancroft, 1990; Tiefer, 1986). Most cases of erectile dysfunction involve physical, psychosocial, and dyadic contributing factors (Burvat et al., 1990; Kaplan, 1983; Kellett, 1995; Masters & Johnson, 1966, 1970; Rosen & Leiblum, 1995). Pfizer (1998) acknowledged in its educational materials that stress, depression, performance expectations, and avoidance must be taken into consideration. Males who present psychogenic erectile dysfunction are more likely to demand rapid medical interventions that may exclude their partners (Kaplan, 1983; Masters & Johnson, 1970). Yet, effective treatment involves improving communication and enhancing intimacy with one’s partner (Barbach, 1997; Hawton et al., 1992; Masters & Johnson, 1970).

The worst case scenario for treatment with viagra (or any medical “quick fix”) involves a physician providing samples or prescribing the medication, then sending the anxious, performance-driven male home to solve his sexual problems. Frequently, the couple has withdrawn from one another. They do not touch or even talk. The female partner may blame herself for the absence of her husband’s response or initiation. The present author is already seeing cases where the male has secretly taken viagra , awaiting a sexual encounter that does not occur. Similarly, having the potential for erection does not insure that the partner is available or their sexual activity is satisfying. Successful treatment of erectile dysfunction and other sexual problems must involve some attention to intimacy enhancement. Pfizer (1998) included in their educational materials, which could be viewed by the male and his partner, remarks from Dr. Gerald R. Weeks, a marital and sex therapist. Dr. Weeks (Pfizer, 1998, pp. 9-11) recommended some activities for improving the relationship and enhancing intimacy. In referring to the roadblocks to sexual health, he noted, “no treatment for ED will make these barriers magically disappear” and “Your relationship needs to be a priority at times” (Pfizer, 1998, p. 11).

Safe, effective medical interventions such as treatment of erectile dysfunction with viagra remove roadblocks to natural sexual functioning and create opportunities to reclaim intimacy in relationships. Use of viagra will be the beginning of a process intended to cultivate emotional and physical closeness in thousands of couples, not the end of an anxiety-driven pursuit to remove a sexual symptom. Although sex therapy lacks definitive research findings and well-established theory (Reynolds, 1977; Rosen & Leiblum, 1995; Weis, 1998), the classic model of Masters and Johnson (1966,1970), with its emphasis on nonsexual touching and open communication, promises to help the field go back to the future.

Technological advances in the 1990s have facilitated careful assessment and reliable treatment for most cases of sexual dysfunction. Specific interventions have been developed for particular types of dysfunction. However, sexual problems evolve in the relational context. Conditioned anxiety, performance pressure, and sexual misconception are common among couples who present for treatment. They would like to regain the natural sexual function. They would also like to enhance the communication and romance in their relationship. Assessment and treatment of sexual dysfunctions should begin with medical examination. Then, sex therapy interventions offered by skilled clinicians can restore intimacy, while removing psychosocial roadblocks to optimal sexual functioning.

Sigusch (1998) discussed a neosexual revolution in which diversification in intimate relationships overcomes the banalization, dissociation, and medicalization of sexuality. Hacker (1990) described a transition from the old norms to the new sexual values of the 1990s in which pleasuring, without the demand for intercourse, heralds a path to caring, respectful behavior between men and women. Perhaps D.H. Lawrence best captured the heart of the “new” sexual health emphasis upon intimacy enhancement in his poem “Wedlock” (de Sola Pinto & Roberts, 1978).

How I love all of you! Do you feel me wrap you
Up with myself and my warmth, like a flame round the wick?
... I spread over you! How lovely your round head, your arms,
Your breasts, your knees and feet! I feel that we
Are a bonfire of oneness, me flame flung leaping round you,
You the core of the fire, crept into me. (p. 245)


Types of Dysfunction by Phase in the Sexual Response Cycle

Legend for Chart: 
	
A - Phase
B - Types of Dysfunction Male
C - Types of Dysfunction Female 
	
A
  B
    C 
	
Desire
  Hypoactive Sexual Desire
  Sexual Aversion
  Sexual Desire Discrepancy
  Sexual Compulsivity
  Paraphilia
    Hypoactive Sexual Desire
    Sexual Aversion
    Sexual Desire Discrepancy
    Sexual Compulsivity
    Paraphilia 
	
Arousal
  Erectile Dysfunction
    Sexual Arousal Disorder 
	
Orgasm
  Delayed Ejaculation
  Rapid Ejaculation
    Anorgasmia 
	
Resolution
  Sexual Compulsivity
  Intimacy Dysfunction
    Sexual Compulsivity
    Intimacy Dysfunction 
	
Pain[*]
  Dyspareunia
    Dyspareunia
    Vaginismus 
	
[*] Pain may occur in several phases, although these conditions
are frequently encountered during attempts at penetration.


REFERENCES

Ackerman, M. D., & Carey, M. P. (1995). Psychology’s role in the assessment of erectile dysfunction: Historical precedents, current knowledge, and methods. Journal of Consulting and Clinical Psychology, 63, 862-876.

Abel, G. G., Huffman, J., Warberg, B., & Holland, C. L. (1998). Visual reaction time and plethysmography as measures of sexual interest in child molesters. Sexual Abuse: Journal of Research and Treatment, 10, 81-95.

Abel, G. G., & Osborn, C. (1992). The paraphilias: The extent and nature of sexually deviant and criminal behavior. Psychiatric Clinics of North America, 15, 675-687.

Abel, G. G., Osborn, C. A., Anthony, D., & Gardos, P. (1992). Current treatment of paraphiliacs. Annual Review of Sex Research, 3, 255-290.

Abel, G., & Roleau, J. L. (1995). Sexual abuses. Psychiatric Clinics of North America, 18, 139-153.

American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.

Anderson, B. L., & Cyranowski, J. M. (1995). Women’s sexuality: Behaviors, responses, and individual differences. Journal of Consulting and Clinical Psychology, 63, 891-906.

Apfelbaum, B. (1989). Retarded ejaculation: A much-misunderstood syndrome. In S. R.

Leiblum & R. C. Rosen (Eds.), Principles and practice of sex therapy: Update for the 1990s (pp. 168-206). New York: Guilford Press.

Ashton, A. K., Hamer, R., & Rosen, R. C. (1997). Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: A large-scale retrospective study of 596 psychiatric outpatients. Journal of Sex and Marital Therapy, 23, 165-175.

Bancroft, J. (1990). Man and his penis: A relationship under threat? Journal of Psychology and Human Sexuality, 2, 6-32.

Barbach, L. (1997). Loving together: Sexual enrichment program. Bristol, PA: Brunner/Mazel.

Beck, J. G. (1995). Hypoactive sexual desire: An overview. Journal of Consulting and Clinical Psychology, 63, 919-927.

Burvat, J., Burvat-Herbaut, M., Lemaire, A., Marcolin, G., & Quittelier, E. (1990). Recent developments in the clinical assessment and diagnosis of erectile dysfunction. Annual Review of Sex Research, 1, 265-308.

Byrne, D., & Schulte, L. (1990). Personality dispositions as mediators of sexual responses. Annual Review of Sex Research, 1, 93-117.

Carnes, P. (1983). Out of the shadows: Understanding sexual addiction. Minneapolis, MN: Compcare.

Carnes, P. J. (1996). Addiction or compulsion: Politics or illness? Sexual Addiction and Compulsivity, 3, 127-150.

Cooper, A. (1998). Sexually compulsive behavior. Contemporary Sexuality, 32, 1-3.

de Sola Pinto, V., & Roberts, E W. (1978). D. H. Lawrence: The complete poems. New York: Penguin Books

Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J., & McKinley, J. B. (1994). Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. Journal of Urology, 151, 54-61.

Guirguis, W. (1998). Oral treatment of erectile dysfunction: From herbal remedies to designer drugs. Journal of Sex and Marital Therapy, 24, 69-73.

Hacker, S. S. (1990). The transition from the old norm to the new: Sexual values for the 1990s. SIECUS Report, 18, 1-8.

Hawton, K., Catalan, J., & Fagg, J. (1992). Sex therapy for erectile dysfunction: Characteristics of couples, treatment outcome, and prognostic factors. Archives of Sexual Behavior, 21, 161-175.

Heiman, J. R., Epps, P. H., & Ellis, B. (1995). Treating sexual desire disorders in couples. In N. S. Jacobson & A. S. Gurman (Eds.), Clinical handbook of couple therapy (pp. 471-495). New York: Guilford.

Heiman, J. R., & LoPiccolo, L. (1988). Becoming orgasmic: A sexual growth program for women. New York: Prentice Hall.

Hirst, J. F., & Watson, J. P. (1997). Therapy for sexual and relationship problems: The effects on outcome of attending as an individual or as a couple. Sexual and Marital Therapy, 12, 321-337.

Kaplan, H. S. (1979). Disorders of sexual desire. New York: Brunner/Mazel.

Kaplan, H. S. (1983). The evaluation of sexual disorders: Psychological and medical aspects. New York: Brunner/Mazel.

Kellett, J. (1995). Functions of a sexual dysfunction clinic. International Review of Psychiatry, 7, 183-190.

Kinzl, J. F., Mangwerth, B., Traweger, C., & Biebl, W. (1996). Sexual dysfunctions in males: Significance of adverse childhood experiences. Child Abuse and Neglect, 20, 759-766.

Kinzl, J. F., Traweger, C., & Biebl, W. (1995). Sexual dysfunctions: Relationship to childhood sexual abuse and early family experiences in a nonclinical sample. Child Abuse and Neglect, 19, 785-792.

Leiblum, S. R., Pervin, L. A., & Campbell, E. H. (1989). The treatment of vaginismus: Success and failure. In S. R. Leiblum & R. C. Rosen (Eds.), Principles and practice of sex therapy: Update for the 1990s (pp. 113-140). New York: Guilford Press.

Lobitz, W. C., & Lobitz, G. K. (1996). Resolving the sexual intimacy paradox: A developmental model for the treatment of sexual desire disorders. Journal of Sex and Marital Therapy, 22, 71-84.

McCabe, M. P. (1997). Intimacy and quality of life among sexually dysfunctional men and women. Journal of Sex and Marital Therapy, 23, 276-290.

McCabe, M. P., & Cobain, M. J. (1998). The impact of individual and relationship factors on sexual dysfunction among males and females. Sexual and Marital Therapy, 13, 131-143.

McCarthy, B. W. (1994). Etiology and treatment of early ejaculation. Journal of Sex and Marital Therapy, 20, 5-6.

McCarthy, B. W. (1997). Chronic sexual dysfunction: Assessment, intervention, and realistic expectations. Journal of Sex Education and Therapy, 22, 51-56.

MacPhee, D. C., Johnson, S. M., & van der Veer, M. M. C. (1995). Low sexual desire in women: The effects of marital therapy. Journal of Sex and Marital Therapy, 21,159-182.

Masters, W. H., & Johnson, V. E. (1966). Human sexual response. Boston, MA: Little, Brown & Co.

Masters, W. H., & Johnson, V. E. (1970). Human sexual inadequacy. New York: Bantam Books.

Meana, M., & Binik, Y. M. (1994). Painful coitus: A review of female dyspareunia. Journal of Nervous and Mental Disease, 182, 264-272.

Melman, A., Tiefer, L., & Pedersen, R. (1988). Evaluation of the first 406 patients in a urology department based center for male sexual dysfunction. Urology, 32, 6-10.

Money, J. (1986). Lovemaps. New York: Irvington Publishers.

Moret, L. B., Glaser, B. A., Page, R. C., Bargeron, E. F. (1998). Intimacy and sexual satisfaction in unmarried couple relationships: A pilot study. The Family Journal: Counseling and Therapy for Couples and Families. 6, 33-39.

Morley, J. E., & Kaiser, F. E. (1993). Impotence: The internist’s approach to diagnosis and treatment. Advances in Internal Medicine, 38, 151-168.

Moser, C. (1992). Lust, lack of desire, and paraphilias: Some thoughts and possible connections. Journal of Sex and Marital Therapy, 18, 65-69.

Palace, E. M. (1995). A cognitive-physiological process model of sexual arousal and response. Clinical Psychology: Science and Practice, 2, 370-384.

Pfizer. (1998,May). The new facts of life. [Videotape and brochure, HX728F97]. (Available from Pfizer U.S. Pharmaceuticals, 235 East 42nd St., New York, NY 10017-5755).

Read, J. (1995). Female sexual dysfunction. International Review of Psychiatry, 7(2), 175-182.

Renshaw, D. C. (1988). Profile of 2,376 patients treated at Loyola Sex Clinic between 1972 and 1987. Sexual and Marital Therapy, 3, 111-117.

Reynolds, B. S. (1977). Psychological treatment models and outcome results for erectile dysfunction. Psychological Bulletin, 84, 1218-1238.

Rosen, R. C., & Leiblum, S. R. (1995). Treatment of sexual disorders in the 1990s: An integrated approach. Journal of Consulting and Clinical Psychology, 63, 877-890.

Rowland, D. L., & Slob, A. K. (1995). Understanding and diagnosing sexual dysfunction: Recent progress through psychophysiological and psychophysical methods. Neuroscience and Biobehavioral Review, 19, 201-209.

Sarwer, D. B., & Durlak, J. A. (1996). Childhood sexual abuse as a predictor of adult female sexual dysfunction: A study of couples seeking sex therapy. Child Abuse and Neglect, 20, 963-972.

Sarwer, D. B., & Durlak, J. A. (1997). A field trial of the effectiveness of behavioral treatment for sexual dysfunction. Journal of Sex and Marital Therapy, 23, 87-97.

Schnarch, D. (1997). Passionate marriage: Sex, love, and intimacy in emotionally committed relationships. New York: W.W. Norton.

Schneider, J. P., & Schneider, B. H. (1996). Couple recovery from sexual addiction/compulsivity: Results of a survey of 88 marriages. Sexual Addiction and Compulsivity, 3, 111-126.

Schwartz, M. F. (1996). Reenactment related to bonding and hypersexuality. Sexual Addiction and Compulsivity, 3, 195-212.

Schwartz, M. F., & Masters, W. H. (1988). Inhibited sexual desire: The Masters and Johnson Institute treatment model. In S. R. Leiblum & R. C. Rosen (Eds.), Sexual desire disorders. (pp. 229-242). New York: Guilford Press.

Seagraves, R. T. (1998). Antidepressant-induced sexual dysfunction. Journal of Clinical Psychiatry, 59, 48-54

Sigusch, V. (1998). The neosexual revolution. Archives of Sexual Behavior, 27, 331-359.

Southern, S. (1985). Hypoactive sexual desire: A cognitive model. Journal of Sex Education and Therapy, 11, 55-60.

Spector, I. P., & Carey, M. P. (1990). Incidence and prevalence of the sexual dysfunctions: A critical review of the empirical literature. Archives of Sexual Behavior, 19, 389-408.

Steege, J. F., & Ling, F. W. (1993). Dyspareunia: A special type of chronic pelvic pain. Obsterics and Gynecology Clinics of North America, 20, 779-793.

Tiefer, L. (1986). In pursuit of the perfect penis: The medicalization of male sexuality. American Behavioral Scientist, 29, 579-599.

Tiefer, L. (1991). Historical, scientific, clinical and feminist criticisms of “the human sexual response cycle” model. Annual Review of Sex Research, 2, 1-23.

Verma, K. K., Khaitan, B. K., & Singh, O. P. (1998). The frequency of sexual dysfunctions in patients attending a sex therapy clinic in North India. Archives of Sexual Behavior, 27, 309-314.

Weis, D. L. (1998). Conclusion: The state of sexual theory. Journal of Sex Research, 35, 100-114.

Whipple, B., Gerdes, C. A., & Komisaruk, B. R. (1996). Sexual response to self-stimulation in women with complete spinal cord injury. Journal of Sex Research, 33, 231-240.

Wilsnack, S. C., Vogeltanz, N. D., Klassen, A. D., & Harris, T. R. (1997). Childhood sexual abuse and women’s substance abuse: National survey findings. Journal of Studies

AAO CAUTIONS VIAGRA USERS OF POSSIBLE VISUAL SIDE EFFECTS

December 31st, 2007

Title: AAO CAUTIONS VIAGRA USERS OF POSSIBLE VISUAL SIDE EFFECTS ,  Ophthalmology Times, 0193032X, 06/01/98, Vol. 23, Issue 11

SAN FRANCISCO–With the recent news of Viagra’s status as a newly approved anti- impotence drug, physicians with the American Academy of Ophthalmology (AAO) are warning users about the potential side effects that may affect vision.

A moderate percentage of people taking Viagra have experienced problems with their vision, said Michael F. Marmor, MD, professor of ophthalmology at Stanford University and spokesperson for the AAO.

“FDA clinical trials show that taking the medication, especially at higher doses, can cause some retinal dysfunction and affect the way we see for a number of hours,” Dr. Marmor said.

Dr. Marmor said a clinical study showed that electrical measures of retinal function dropped by 30% to 50% and lasted for at least five hours after patients took a high dose of Viagra. Patients reported visual disturbances described as bluish-color tinge and light sensitivity.

“On the surface, seeing the world with a bluish tinge may just be annoying,” Dr. Marmor said. However, it is not known whether the drug causes any permanent changes in vision.

“We need to do some studies about the long-term effects of taking Viagra,” he said.

Dr. Marmor urged people with retinal conditions such as macular degeneration or retinitis pigmentosa to use the drug with caution.

“Stay at the lowest dose level possible,” Dr. Marmor said.

According to the FDA, the recommended dose level for most patients is 50 mg.

~~~~~~~~

FROM STAFF REPORTS


Copyright of Ophthalmology Times is the property of Advanstar Communications Inc. and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Ophthalmology Times, 06/01/98, Vol. 23 Issue 11, p3, 1p

SOME UNEXPECTED RELIEF FOR ENDANGERED SPECIES

December 31st, 2007

Title: SOME UNEXPECTED RELIEF FOR ENDANGERED SPECIES ,  By: Prusher, Ilene R., Christian Science Monitor, 08827729, 5/29/2001, Vol. 93, Issue 128

Section: WORLD



When Viagra came out, biologists hoped demand for endangered animals would drop. New evidence may support this controversial theory

Dateline: YOKOHAMA, JAPAN

The packages on Makoku Kins’s shelves come in dragonlady red with gold, or bright blue. Many contain parts from some of world’s most endangered species.

Chinese-medicine practitioners around Asia have long placed faith in pu foods, which come from animal parts coveted for their purported aphrodisiac properties. These include bones or other parts of animals - such as bears, tigers, monkeys, and whales - whose survival on earth wasn’t a question when they first became used medicinally.

The international trade in endangered species is partially fueled by demand for such animal parts both for medicinal and aphrodesiac purposes. Ever since the drug Viagra came to market in 1998, conservationists have speculated that it might stem the trade in endangered animals. “In Viagra we now have the potential to eliminate the demand for animal potency products,” wrote Frank von Hippel, a conservation biologist, in a 1998 article in Science magazine. “Provided that the distribution and availability of Viagra are ensured, the East Asian market in pu foods could soon fall victim to Viagra’s success.”

Some early signs support this theory, but it remains controversial.

A study released in February by Canada’s Department of Fisheries and Oceans links the advent of Viagra with a decrease in the killing of harbor seals - which aren’t endangered - for use in aphrodisiacs in Asia. Seal penises are thought to increase male virility. According to the Canadian scientists, some 91,000 seals were killed off Newfoundland and Quebec last year - just a third of the legal quota - compared with 280,000 a few years earlier. After the researchers at the Eminent Seal Panel discovered the sharp decrease in the number of seals killed, they raised the possibility that the seals had Viagra to thank.

“The reduced hunt in 2000 was the result of a number of factors,” they wrote. “The increased use of Viagra, as a substitute for seal penises, may also be a factor.” The study also suggests that other factors played a role in the dwindling numbers, including a decreased demand for seal meat and a cut in Canadian government subsidies for seal hunting.

In a new, unpublished study, Professor Hippel and his brother, an Ohio State University psychologist, offer an extensive analysis of which species are likely to benefit from Viagra. “We found in that analysis that rhinos, bears, and tigers will not benefit, but that many other species will, including … seals,” says Mr. Hippel, who teaches conservation biology and environmental science at the University of Alaska, in Anchorage.

But some conservation groups suggest that such theories are in need of a cold shower.


Not enough evidence

Nathalie Chalifour, the acting national representative for TRAFFIC Canada, the wildlife-trade monitoring program of the World Wildlife Fund, says that the seals in question are primarily killed for their pelts and meat.

While there has been a decline in demand for both, Ms. Chalifour notes, there is little evidence that seals are killed for the express purpose of being turned into Asian philters.

“My understanding to date is that the seal hunt has never been targeted at the seal penis trade. All the anecdotal evidence that I’ve come across is that the sealers will sell them if they can, but it’s not the driver,” says Chalifour. “Unless they can show that the hunt is targeted to penises, perhaps there’s a link, but it’s pretty tenuous.”

Meanwhile, dealers in traditional Chinese medicines say they don’t think any laboratory-concocted drug will replace demand for their timeworn remedies.

While pu is hardly a household name here in Japan, many come to pharmacies like this one in search of kanpoyaku, or Chinese medicine, the vast bulk of which is purely herbal.

“This is a totally different thing,” says Mr. Kin, who wears a pharmacist’s white lab coat and a tidy haircut, as he reads over the back panel of one of his more popular products. His shelves are lined with packages, some of which picture snakes and turtles, others a photo of an aging executive in a business suit flexing his arms, muscle-man style.

Kin’s pharmacy specializes in Chinese medicines, but also carries many internationally recognized drugs. It is one of many such shops around Yokohama, home to Japan’s largest Chinatown and the country’s main port.

“Viagra is something to be taken at a particular time, but this,” says Kin, holding up a huge bottle of pills that goes for about $170, “this you take every day to make your body stronger. Once you’re taking this, you don’t have to take Viagra.”


No substitute for the ‘real thing’

Kin says that Japanese customers often come looking for herbal and animal-based medicines when a trip to a physician yields no results. “In China, it’s the opposite,” he says of his homeland. But Kin says he isn’t losing business to Pfizer, the manufacturer of Viagra. “I’ve never heard of anyone quitting this and taking Viagra instead.”

Merchants in Chinatown seem to agree. A few blocks away from Mr. Kin’s pharmacy is a traditional Chinese foods store where some people come for basic sauces and spices - and sometimes for far stronger stuff. But most aphrodisiac seekers, says shopkeeper Sai Soo, turn to the extract of seal, tiger, and bear in multivitamin-style pills only.

Mr. Soo’s shelves are lined with glass jars full of sundry goods such as dehydrated seahorse, snail, and sharkfin - all used to make various medicinal soups and drinks.

“Chinese people have an older way of looking at things - to eat something is a way to cure yourself. It might not be something that the international community accepts, but a lot of people believe shark fins are good for your skin and tiger bones are good for calcium.”

But very few, he admits, come looking for the aphrodisiac foods in whole form, “mostly,” he says, “because they wouldn’t know how to cook with them.”

PHOTO (COLOR): ABUND